Letko, Brosseau & Associates
PVLA icon

Letko, Brosseau & Associates’s Palvella Therapeutics PVLA Stock Holding History

Letko, Brosseau & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Hold
3,500
– – 0.01% 80
2026
Q1 		$436K Hold
3,500
– – 0.01% 80
2025
Q4 		$366K Sell
3,500
-1,700
-33% -$145K 0.01% 82
2025
Q3 		$326K Buy
+5,200
New +$232K 0.01% 83

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Letko, Brosseau & Associates's PVLA Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 3,500 shares worth $535K. The position accounts for 0.01% of the portfolio, ranked #80.

Letko, Brosseau & Associates first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Letko, Brosseau & Associates held 3,500 shares of Palvella Therapeutics worth $535K as of Q2 2026.
  • Letko, Brosseau & Associates left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up 0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #80 holding.
  • Letko, Brosseau & Associates first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.